14159 capital (GP), LLC
CIK 1317493 · last filed 2012-03-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$43.95M
Companies
13
Total Filings
59
Lifetime Open-Market Net
$6.15M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 4,609 | — | — | $243.5K | 1 | 2012-03-14 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 215,669 | — | — | $4.35M | 15 | 2012-02-29 |
| INCY | Director | 344,064 | $117.67 | $40.49M | -$303.0K | 12 | 2012-01-17 |
| Seagen Inc. (SGEN) Delisted | Director | 323,148 | $228.74 | $73.92M | $2.01M | 5 | 2011-09-08 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 143,568 | — | — | -$430.3K | 3 | 2011-08-03 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 93,282 | — | — | $801.3K | 2 | 2011-01-24 |
| RPRX | 10%+ Owner | 38,386 | $58.83 | $2.26M | $49.1K | 1 | 2010-04-28 |
| BCRX | 10%+ Owner | 128,783 | $9.34 | $1.20M | -$200.9K | 1 | 2009-06-01 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 187,491 | — | — | -$467.3K | 4 | 2009-05-26 |
| Aceragen, Inc. (IDRA) Delisted | 10%+ Owner | 928 | $7.22 | $6.7K | -$112.9K | 2 | 2008-07-21 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 264,699 | — | — | $309.2K | 3 | 2008-05-27 |
| TAPESTRY PHARMACEUTICALS, INC (TPPH) Delisted | 10%+ Owner | 112,451 | — | — | -$473 | 1 | 2008-04-08 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 31,708 | — | — | -$101.7K | 3 | 2007-12-07 |
Recent Filings · Page 5 of 6
59 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2008-02-21 | ALLOS THERAPEUTICS INC (ALTH) Delisted | Buy (P) | +24,030 | $152.4K | EDGAR |
| 2008-02-11 | Seagen Inc. (SGEN) Delisted | Buy (P) | +14,649 | $132.1K | EDGAR |
| 2008-01-24 | INCY | Buy (P) | +21 | $223 | EDGAR |
| 2008-01-11 | INCY | Buy (P) | +11,673 | $127.7K | EDGAR |
| 2008-01-10 | VIROPHARMA INC (VPHM) Delisted | Buy (P) | +16,536 | $146.1K | EDGAR |
| 2008-01-04 | Aceragen, Inc. (IDRA) Delisted | Sell (S) | −4,782 | -$62.4K | EDGAR |
| 2007-12-12 | INCY | Buy (P) | +27,538 | $275.1K | EDGAR |
| 2007-12-07 | Aceragen, Inc. (IDP) Delisted | Sell (S) | −4,221 | -$52.0K | EDGAR |
| 2007-12-06 | INCY | Buy (P) | +3,624 | $32.6K | EDGAR |
| 2007-11-21 | INCY | Buy (P) | +17,628 | $144.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.